Metaphore Biotechnologies
Metaphore Biotechnologies is a Cambridge-based preclinical biotech that uses its MIMIC platform, combining large-scale live-cell experimentation with machine learning, to design functional antibodies for autoimmune, metabolic, and oncology indications, pursuing development primarily through pharma partnerships.
- Company typePrivate
- Founded2021
- HeadquartersCambridge, United States
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What Metaphore Biotechnologies does
Metaphore Biotechnologies is a Cambridge, Massachusetts-based preclinical biotechnology company that originated in 2021 inside Flagship Labs (the innovation foundry of Flagship Pioneering) and publicly launched in May 2023 with a $50 million Series A commitment from Flagship. The company develops functional antibodies for patients with autoimmune, metabolic, and oncologic diseases, focusing on therapeutic targets that conventional structure-based antibody design cannot reach.
The company's core asset is the MIMIC™ (Molecular Mimicry) platform, a computationally driven bioplatform that combines large-scale live-cell experimentation with machine learning. The platform operates in three tightly connected stages: MAP measures protein behavior inside living cells at massive scale, generating billions of interaction points; MIMIC uses machine learning models to interpret those functional maps and identify features driving biological outcomes such as agonism, signaling bias, selectivity, and multi-receptor engagement; DESIGN then creates new antibodies with precisely defined functional behaviors, including pathway activation, multi-target engagement, and tunable signaling. Metaphore positions the platform against the ~95% of therapeutic antibodies that work only by blocking biology, targeting the residual opportunity in functional antibody design.
Metaphore is pre-revenue and operates a partnership-led business model aimed at licensing and co-development rather than direct product sales. The company's flagship commercial relationship is an October 2024 research collaboration with Novo Nordisk to design up to two next-generation long-acting, multi-targeting therapeutics in the GLP-1 receptor space for obesity management. Leadership has been substantially rebuilt around commercial and drug-discovery veterans: Angela Hwang (former Pfizer Chief Commercial Officer) became CEO effective January 1, 2025; Anabella Villalobos (ex-Biogen/Pfizer) joined as CSO in September 2025; Paul Weinreb (ex-Biogen, co-inventor of aducanumab) joined as SVP in November 2025. The company received its first disclosed external capital from TOHO Ventures (operated by Global Brain) in April 2026, while Flagship Pioneering remains the controlling shareholder.
Metaphore Biotechnologies firmographics
Firmographics- Name
- Metaphore Biotechnologies
- Legal name
- Metaphore Biotechnologies
- Website
- https://metaphorebio.com
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Metaphore Biotechnologies is a Cambridge-based preclinical biotech that uses its MIMIC platform, combining large-scale live-cell experimentation with machine learning, to design functional antibodies for autoimmune, metabolic, and oncology indications, pursuing development primarily through pharma partnerships.
- Ownership category
- akta.pro rank
Metaphore Biotechnologies industry classification
Industry- Product category
- Biotechnology - Computational Antibody Drug Discovery
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)
- akta.pro secondary industries
- Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB), Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization) (HLAAAIAC), Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds) (HLAAAAAJ)
Keywords
Where Metaphore Biotechnologies is headquartered
LocationHeadquarters
- HQ city
- Cambridge
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Metaphore Biotechnologies business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
Revenue model
- Therapeutic Development and Licensing: Pre-revenue biotech developing proprietary therapeutics pipeline. Revenue will likely come from licensing agreements, co-development partnerships, and eventual product sales. Strategic collaboration with Novo Nordisk in GLP1-R biology space represents early partnership model.
Go-to-market motion2 records
Distribution channels1 record
Marketing channels5 records
Metaphore Biotechnologies product offering
Product offeringCore offering
Metaphore Biotechnologies develops the MIMIC™ platform, a computationally driven bioplatform that combines high-throughput live-cell experimentation with machine learning to design functional antibodies. The platform uses three stages (MAP, MIMIC, DESIGN) to generate antibody candidates capable of activating pathways, tuning signaling bias, and engaging multiple receptors. The company focuses on therapeutic pipelines for autoimmune, metabolic, and oncology indications, pursuing partnerships with large pharmaceutical companies.
Product overview
Metaphore Biotechnologies offers a single unified platform called MIMIC™ (Molecular Mimicry Platform), which is a computationally driven bioplatform for designing functional antibodies. The platform combines large-scale live-cell experimentation with machine learning to design biologics that can activate pathways, tune signaling, or engage multiple targets, moving beyond the traditional 95% of therapeutic antibodies that work only by blocking biology. The platform operates through three connected stages: MAP (measuring protein behavior at massive scale in living cells), MIMIC (machine learning interpretation to identify functional features), and DESIGN (creating antibodies with precisely defined functional behaviors).
Differentiator
Problem solved
Functional benefit
Products and services
- MIMIC™ Platform A computationally driven bioplatform that combines high-throughput live-cell experimentation with machine learning to design functional antibodies beyond simple blocking mechanisms. Operates through three stages (MAP, MIMIC, DESIGN) to generate optimized antibody candidates in weeks instead of years.
Quantifiable outcome
- Optimized molecules generated in weeks instead of years through the MAP-MIMIC-DESIGN iterative platform cycle
Companies that use Metaphore Biotechnologies
Customer profileSegments1 record
Ideal customer profiles2 records
Metaphore Biotechnologies technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability5 records
Feature5 records
Metaphore Biotechnologies partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Novo NordiskcoreMetaphore announced a research collaboration with Novo Nordisk to develop up to two next-generation long-acting, multi-targeting therapeutics in the GLP1-R biology space for obesity management. The collaboration leverages Metaphore's unique MIMIC platform to design next-generation therapeutics.
Scale indicators3 records
Recent moves6 records
Expansion highlights5 records
Metaphore Biotechnologies competitors and assessment
Company assessmentBroad incumbents
- Isomorphic Labs: Isomorphic Labs (an Alphabet subsidiary) is applying DeepMind's AI capabilities to drug discovery and protein structure prediction. It is a broader incumbent with significant resources pursuing AI-enabled therapeutic design, overlapping with Metaphore's computational biology approach.
- Insitro: Insitro uses machine learning and high-throughput biology to rethink drug discovery across multiple therapeutic areas. While its initial focus is on small molecules and cell therapies, its machine-learning-driven approach to biology positions it as an adjacent platform competitor.
- Recursion Pharmaceuticals: Recursion combines high-throughput biology, chemistry, and AI to discover and develop medicines at scale. While broader in therapeutic modality, Recursion's automated biology + ML approach is comparable to Metaphore's platform thesis of compressing drug discovery timelines through data-driven experimentation.
Direct peers
- Adimab: Adimab operates a proprietary antibody discovery and engineering platform that partners with major pharmaceutical companies. Its business model of platform-based antibody discovery partnerships is directly comparable to Metaphore's enterprise partnership GTM.
- BigHat Biosciences: BigHat Biosciences combines wet-lab high-throughput antibody synthesis with machine learning to engineer safer, more effective antibody therapeutics. Its AI-driven antibody design approach and focus on functional antibody engineering closely parallel Metaphore's MIMIC platform.
- AbCellera: AbCellera is a clinical-stage biotech with a leading antibody discovery platform that combines high-throughput screening, microfluidics, and AI/ML. It serves as a major pharma partner for antibody discovery, directly competing for similar partnership economics to Metaphore.
- Generate Biomedicines: Generate Biomedicines is a Flagship Pioneering company that uses machine learning to program protein-based therapeutics, including generative biology to design novel functional proteins. It is the most directly comparable platform to Metaphore in both technology approach and Flagship ecosystem origin.
- Cradle Bio: Cradle (previously Cradle Biosciences) uses generative AI and high-throughput experimentation to design and optimize proteins, including antibodies and enzymes. Its platform approach combining ML with wet-lab data is structurally similar to Metaphore's MIMIC.
Emerging players
- EvolutionaryScale: EvolutionaryScale is an AI research company focused on frontier biological AI models (e.g., ESM3) for protein design and engineering. While it is a newer entrant, its mission of programming biology with AI makes it a relevant emerging competitor to MIMIC's AI/ML-enabled antibody design.
Others
- Alltrna: Alltrna is a Flagship Pioneering company developing tRNA-based therapeutics. It is a sibling Flagship company with shared origination and platform approach, making it a useful reference for Flagship's company-building model, though its tRNA modality differs from Metaphore's antibody focus.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Metaphore Biotechnologies social profiles
Digital presenceMetaphore Biotechnologies financial estimates
Financial estimateRevenue estimate
Valuation estimate
Metaphore Biotechnologies leadership team
Management profileNumber of profiles
Profiles7 records
Metaphore Biotechnologies funding detail
Funding detailFunding overview
Funding rounds3 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Metaphore Biotechnologies M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Metaphore Biotechnologies
What does Metaphore Biotechnologies do?
Metaphore Biotechnologies develops the MIMIC™ platform, a computationally driven bioplatform that combines high-throughput live-cell experimentation with machine learning to design functional antibodies. The platform uses three stages (MAP, MIMIC, DESIGN) to generate antibody candidates capable of activating pathways, tuning signaling bias, and engaging multiple receptors. The company focuses on therapeutic pipelines for autoimmune, metabolic, and oncology indications, pursuing partnerships with large pharmaceutical companies.
Is Metaphore Biotechnologies a public or private company?
Metaphore Biotechnologies is a private company. It is classified as venture growth investor backed and is currently operating.
When was Metaphore Biotechnologies founded?
Metaphore Biotechnologies was founded in 2021. It employs 11 to 50 people.
Where is Metaphore Biotechnologies based?
Metaphore Biotechnologies is headquartered in Cambridge, United States, in the North America region.
How does Metaphore Biotechnologies make money?
One revenue line is on record: therapeutic Development and Licensing.
Who are Metaphore Biotechnologies's main competitors?
Broad incumbents on record are Isomorphic Labs, Insitro and Recursion Pharmaceuticals. Direct peers are Adimab, BigHat Biosciences, AbCellera, Generate Biomedicines and Cradle Bio. EvolutionaryScale is listed as an emerging player. Alltrna is listed as an others.
Does Metaphore Biotechnologies have an API?
No public API is recorded for Metaphore Biotechnologies.
What industry is Metaphore Biotechnologies in?
Metaphore Biotechnologies's product category is Biotechnology - Computational Antibody Drug Discovery. Its primary akta.pro industry code is HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening), with a secondary code of HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering). Its NAICS code is 325414 and its SIC code is 2836.